• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Advisory Committees

  • Print
  • Share
  • E-mail

Agenda

BLOOD PRODUCTS ADVISORY COMMITTEE
103rd Meeting, June 12, 2012

National Institutes of Health
Building 29, Conference room 29-121

Tuesday, June 12, 2012

12:00 p.m. 

Opening Remarks, Blaine Hollinger, M.D., Chair

Statement of Conflicts of Interest, Announcements

12:10 p.m.

Topic I:  Review of the Research Programs in the Laboratories of Emerging Pathogens and Bacterial and
Transmissible Spongiform Encephalopathy Agents, Division of Emerging and Transfusion Transmitted Diseases, OBRR

  1. Overview of CBER Research, Carolyn Wilson, Ph.D., CBER, FDA (15’)
  2. Overview of the Division of Emerging and Transfusion Transmitted Diseases Research Program, Hira Nakhasi, Ph.D., DETTD, OBRR, FDA (15’)
  3. Overview of the Laboratory of Emerging Pathogens (LEP), Sanjai Kumar, Ph.D., DETTD, OBRR, FDA (60’)

Questions & Answers (10’)

  1. Overview of the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents (LBTSEA), David  Asher, M.D., DETTD, OBRR, FDA (30’)

Questions and Answers (10')

2:30 p.m.Open Public Hearing
3:30 p.m.Break
3:45 p.m.Closed Committee Discussion
4:30 p.m.Adjournment